Skip to main content

News of Note—Johnson & Johnson, Bavarian Nordic and more

newspaper
In this week's news of note, Johnson & Johnson announced a data publication for its "mosaic-based" HIV vaccine. (Pixabay)

Here is some other vaccine news of note for the week:

> Johnson & Johnson announced that The Lancet published data from its phase 1/2b study of a "mosaic-based" HIV vaccine. The company advanced the shot to an efficacy test last November. Release | FiercePharma article

> Bavarian Nordic announced that a phase 2 trial of the company's cancer vaccine CV301 and Bristol-Myers Squibb's Opdivo started in patients with resectable hepatic-limited metastatic colorectal cancer. Release

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> MabVax licensed an antibody development program for multiple cancers to Boehringer Ingelheim for $11 million upfront, plus undisclosed milestones. Release

> Even though Neovacs' therapeutic lupus vaccine missed a primary efficacy endpoint in a phase 2b study, the company is moving into phase 3 based on other results. Release

> Altimmune named Mitchel Sayare, Ph.D., its executive chairman and José Ochoa its chief business officer. Release

Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.